Want to see HK:8622 full AI Analyst Report?

Huakang Biomedical Holdings Company Limited (8622) Price & Analysis

0 Followers

8622 Stock Chart & Stats

HK$0.42

HK$0.01(7.32%)

At close: Jan 09 4:00 PM EST

HK$0.42

HK$0.01(7.32%)

Day’s Range― - ―

52-Week RangeHK$0.15 - HK$0.75

Previous CloseN/A

Volume952.00K

Average Volume (3M)153.33K

Market Cap

HK$101.03M

Enterprise ValueHK$67.16

Total Cash (Recent Filing)HK$39.23M

Total Debt (Recent Filing)HK$7.66M

Price to Earnings (P/E)―

Beta0.38

Next Earnings

Mar 25, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding515,472,000

10 Day Avg. Volume189,600

30 Day Avg. Volume153,333

Financial Highlights & Ratios

PEG Ratio-2.40

Price to Book (P/B)3.83

Price to Sales (P/S)6.93

P/FCF Ratio-59.52

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong Revenue GrowthRapid top-line growth indicates expanding demand and market reach, giving the company a larger revenue base from which to build scale. If this growth persists, it could support operating leverage and improve the ability to convert strong product economics into future profitability.

Resilient Gross MarginsSustained gross margins in the 62–67% range demonstrate attractive underlying product economics and provide meaningful room to cover operating expenses. This margin structure is a durable advantage because continued revenue expansion could eventually translate into stronger earnings if cost discipline improves.

Manageable LeverageLow leverage gives Huakang Biomedical greater financial flexibility than a heavily indebted business, reducing pressure from debt servicing and refinancing. Stable assets and equity also suggest no obvious balance-sheet deterioration, preserving capacity to fund operations while pursuing growth.

Bears Say

Persistent Operating LossesPersistent operating and net losses show that strong revenue growth has not yet produced operating leverage or sustainable earnings. Continued losses can constrain reinvestment, weaken returns on the business model, and make future profitability dependent on substantial improvement in cost control and scale.

Recurring Cash BurnNegative operating and free cash flow means the business is currently consuming cash rather than funding itself internally. Although free cash flow is improving from a negative base, continued cash burn could limit strategic flexibility and increase the need for external funding if losses persist.

Negative Returns On EquityA negative return on equity indicates that the company is not currently generating profits from the capital invested in it. This weak capital productivity reinforces the profitability concern and suggests that balance-sheet resources are not yet producing adequate economic returns for shareholders.

8622 FAQ

What was Huakang Biomedical Holdings Company Limited’s price range in the past 12 months?

Huakang Biomedical Holdings Company Limited lowest stock price was HK$0.15 and its highest was HK$0.75 in the past 12 months.

What is Huakang Biomedical Holdings Company Limited’s market cap?

Huakang Biomedical Holdings Company Limited’s market cap is HK$101.03M.

When is Huakang Biomedical Holdings Company Limited’s upcoming earnings report date?

Huakang Biomedical Holdings Company Limited’s upcoming earnings report date is Mar 25, 2027 which is in 183 days.

How were Huakang Biomedical Holdings Company Limited’s earnings last quarter?

Huakang Biomedical Holdings Company Limited released its earnings results on Aug 28, 2026. The company reported -HK$0.005 earnings per share for the quarter.

Is Huakang Biomedical Holdings Company Limited overvalued?

According to Wall Street analysts Huakang Biomedical Holdings Company Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Huakang Biomedical Holdings Company Limited pay dividends?

Huakang Biomedical Holdings Company Limited does not currently pay dividends.

What is Huakang Biomedical Holdings Company Limited’s EPS estimate?

Huakang Biomedical Holdings Company Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Huakang Biomedical Holdings Company Limited have?

Huakang Biomedical Holdings Company Limited has 515,472,000 shares outstanding.

What happened to Huakang Biomedical Holdings Company Limited’s price movement after its last earnings report?

Huakang Biomedical Holdings Company Limited reported an EPS of -HK$0.005 in its last earnings report. Following the earnings report the stock price went up 3.125%.

Which hedge fund is a major shareholder of Huakang Biomedical Holdings Company Limited?

Currently, no hedge funds are holding shares in HK:8622

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Huakang Biomedical Holdings Company Limited Stock Smart Score

Underperform

Technicals

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

4.66%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Huakang Biomedical Holdings Company Limited

Huakang Biomedical Holdings Company Limited operates as an investment holding firm, primarily dedicated to the research, development, manufacturing, marketing, and distribution of in-vitro diagnostic (IVD) reagents within the People's Republic of China. Its comprehensive product portfolio encompasses IVD reagents designed for assessing male and female fertility, detecting parasite antibodies, and identifying the Epstein-Barr virus. Additionally, the company provides auxiliary reproductive supplies and equipment, alongside a range of healthcare products and nutritional supplements marketed under its 'Nutronic' brand, which are sold through both digital and physical platforms. Products are distributed directly to hospitals and medical institutions, as well as through a network of third-party distributors. The company was founded in 1992 and maintains its headquarters in Wan Chai, Hong Kong.